BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Core Insights - BriaCell Therapeutics Corp. announced the complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, a personalized off-the-shelf immunotherapy [1][2][6] Group 1: Patient Outcomes - The first patient in the Bria-OTS study, a 78-year-old woman with advanced MBC, achieved a 100% resolution of a lung metastasis after four doses of Bria-OTS therapy [2] - The complete response was confirmed at multiple intervals: 2 months, 4 months, 6 months, and now at 11 months [2][3] - The patient received a total of 17 cycles of Bria-OTS and completed 12 months of the study, remaining in survival follow-up [2] Group 2: Study Progress - The Phase 1 dose escalation portion of the Bria-OTS study is complete, and the Phase 2a portion, which evaluates the combination of Bria-OTS with an immune checkpoint inhibitor, is currently underway [5][9] - The clinical findings from the study have reinforced confidence in the therapeutic potential and safety of the Bria-OTS platform [6] Group 3: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [10]